NCT02261116已完成4 期
Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Slope of PRA increase versus DR-1
研究概览
简要总结
Study to assess potential different properties of telmisartan, which due to its Vd, should result in stronger "beneficial" effects of AT1 blockade in tissues (e.g. aldosterone suppression and renin increase) plus stronger AT2 stimulation compared to candesartan
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males, aged 18 to 45 years.
- •Absence of any relevant disease as determined by no clinically deviation from normal in medical history, clinical laboratory determination, ECGs and physical examinations
- •Systolic blood pressure (SBP) between 100 and 140 mmHg systolic and below 85 mmHg diastolic (both left and right arm) and a heart rate of ≥50 bpm
- •Signed informed consent form
- •No intake of drugs inbetween a waiting time of ten times of half-life
排除标准
- •Contraindications to Ang II antagonists, known hypersensitivity, history of angioedema, serious allergy, asthma, allergic skin rash, significant allergic rhinitis or sensitivity to any drug
- •History of cardiovascular diseases: any clinically significant cardio-vascular disease, a supine diastolic blood pressure >86 mmHg and systolic >141 mmHg measured by a standard sphygmomanometer or a heart rate ≤49 bpm
- •Cerebrovascular diseases: history of stroke or transitory ischemic attacks (TIAs) or history of any cerebral bleeding
- •Renal diseases: serum creatinine >1.5 mg/dL
- •Gastrointestinal/Hepatic diseases: Aspartate aminotransferase (ASAT) >40 U/l or Alanine aminotransferase (ALAT) >40 U/L, serum bilirubin >2x upper limit of normal, history of malabsorption or inability to tolerate oral medication, history of gastric or duodenal ulcers, history of significant gastrointestinal bleeding, history of hepatitis within the past years
- •Any history of alcohol or drug abuse
- •Use of any of the following drugs within 4 weeks of study enrolment (e.g. agents known to induce drug metabolizing enzymes): anabolic steroids and corticoids, antiarrhythmics (amiodarone, mexiletine, quinidine, propafenone), antibiotics (chloramphenicol, tetracyclines, sulfonamides, macrolides, cephalosporins, rifampicin, nalidixic acid), antiepileptics (phenytoin, carbamazepine), antifungals (e.g. griseofulvin), barbiturates, cimetidine, ethacrynic acid, fibrates, furosemide, haloperidol, lipid lowering agents (cholestyramine, hydroxymethylglutaryl, coenzyme A (HMG CoA) reductase inhibitors, dextrothyroxin), thyroid replacement therapy hormones or thyrostatics (thioureylene-type). The use of nonsteroidal antiinflammatory drugs (NSAIDs) should be discontinued 2 weeks prior to study enrolment, the one exception of aspirin should be one (1) week prior to study enrolment
- •Participation in any other investigational study, within the 30 days prior to enrolment
- •Blood donation within the previous 3 months
- •The investigator might disqualify a subject for a sound medical or psychiatric reason
研究组 & 干预措施
Telmisartan
Experimental
干预措施: Telmisartan (Drug)
Candesartan
Active Comparator
干预措施: Candesartan (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Slope of PRA increase versus DR-1
时间窗: Predose and 2, 4, 8 h following trial medication
analysis of variance
次要结局
- Assessment of angiotensin-1 (AT1) pressor antagonism in vivo (DR-1)(Predose and 2, 4, 8 h following trial medication)
- Reactive response of the plasma renin activity (PRA)(Predose and 2, 4, 8 h following trial medication)
- Number of subjects with adverse events(up to 42 days)
- Assessment of plasma aldosterone concentration after stimulation with Angiotensin II(Predose and 2, 4, 8 h following trial medication)
研究者
相似试验
终止
不适用
Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive PatientsHypertensionAcute Coronary SyndromeAcute Myocardial InfarctionAngina PectorisMyocardial IschemiaNCT00863980Kyoto Prefectural University of Medicine1,500
已完成
不适用
Effects of Telmisartan compared with Candesartan on ischemic cardiovascular events in high-risk hypertensive patients: a multi-center, prospective, randomized, open-labeled, blinded endpoints trialEssential hypertensionJPRN-UMIN000001762Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine1,500
进行中（未招募）
1 期
Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure - Sartans and glucosemetabolismEUCTR2005-002109-22-ATMedical University of Vienna99
已完成
1 期
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant UseHealthyNCT01344629Boehringer Ingelheim64
已完成
不适用
TELMA - Observational Study in Daily Medical Practice of the Effectiveness of Telmisartan for Treatment of Hypertension in Patients With and Without Confirmed Albuminuria in BelgiumHypertensionNCT00886288Boehringer Ingelheim2,874